Sponsored by
LOS ANGELES, CA -- (MARKET WIRE) -- 05/17/2006 -- OncoMune announced today that Chief Scientific Officer Anahit Ghochikyan, Ph.D. presented data which demonstrates unequivocally for the first time the ability of a cancer vaccine to induce tumor regression by targeting a novel class of proteins called "epigenetic regulators of transcription." The vaccine, OCM-111™, represents a unique approach to cancer therapy which causes the eradication of tumor cells while preventing their mutation to escape the vaccine's effect.
The talk occurred at the American Association of Immunologists Annual Meeting, on May 14th in Boston. This meeting is the largest gathering of immunologists and was attended by over 15,000 scientists.
"These findings confirm our initial observations that the set of cancer-specific targets developed by OncoMune are not only recognized by the immune system, but also play an essential role in the survival of the cancer," said Dr. Ghochikyan. "By teaching the immune system to specifically seek and destroy cells expressing our novel target, we can spare patients of toxicity and side effects associated with more conventional cancer treatment approaches."
"We are excited not only about the strong data that Dr Ghochikyan has presented, but also about the widespread acceptance of our novel approach by the international scientific community," said Dr Gary Reznik, President of OncoMune. "This presentation is one of several upcoming peer-reviewed disclosures of OncoMune pipeline candidates that are anticipated to be revealed in the upcoming months," concluded Dr Reznik.
About OncoMune: OncoMune LLC (OncoMune) is a start-up biotechnology company focused on "Defeating Cancer through Immune Modulation." The company's mission is to commercialize therapeutics that can eliminate the burden of a wide range of cancers by utilizing the molecular and cellular mechanisms of a patient's own immune system. OncoMune's lead product is OCM-111™, a cancer vaccine that has demonstrated ability to induce anti-tumor T cells that are effective against breast cancer, leukemia and glioma. Additionally, OCM-111 can potentially help treat colorectal, renal, lung and ovarian cancers, as well as melanoma.
Contact Information: Paul Nagourney (786) 999-2247 Email Contact www.oncomune.com
SOURCE: bioRASI